Vernalis Plc is a research and development stage pharmaceutical company. The company provides pharmaceutical products for a range of medical disorders. It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development. The group has one marketed product, frovatriptan, for the acute treatment of migraines, as well as eight programmes in its NCE development pipeline. The company was founded by Keith G. McCullagh in 1986 and is headquartered in Wokingham, the United Kingdom.